Glucagon-like peptide-1 (GLP-1): Effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 4, 2013, Pages

  Skov, Jeppe ^a,b   Dejgaard, Anders ^b   Frøkiær, Jørgen ^a   Holst, Jens Juul ^c   Jonassen, Thomas ^c   Rittig, Søren ^a   Christiansen, Jens Sandahl ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b NOVO NORDISK A S   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN II; ANGIOTENSINOGEN; EDETATE CHROMIUM CR 51; GLUCAGON LIKE PEPTIDE 1; IODOHIPPURATE SODIUM I 123; LITHIUM; RENIN; SODIUM;

ADULT; ANGIOTENSIN BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INFUSION; GLOMERULUS FILTRATION RATE; HEART RATE; HUMAN; KIDNEY BLOOD FLOW; KIDNEY CLEARANCE; KIDNEY FUNCTION; KIDNEY PLASMA FLOW; KIDNEY TUBULE ABSORPTION; MALE; MICTURITION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM ABSORPTION; SODIUM URINE LEVEL; TREATMENT DURATION; URINARY EXCRETION;

ADULT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; GLOMERULAR FILTRATION RATE; GLUCAGON-LIKE PEPTIDE 1; HEALTH; HEMODYNAMICS; HUMANS; KIDNEY; MALE; PLACEBOS; REGIONAL BLOOD FLOW; RENIN-ANGIOTENSIN SYSTEM; URINALYSIS; YOUNG ADULT;

EID: 84876266256     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3855     Document Type: Article

References (36)

1. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409-1439.
2. Garber AJ. Incretin-based therapies in the management of type 2 diabetes: rationale and realityinamanaged care setting. Am J Manag Care. 2010;16(7 suppl):S187-S194.
3. Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771.
4. Bullock BP, Heller RS, Habener JF. Tissue distribution ofmessenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology. 1996;137(7):2968-2978.
5. Körner M, Stöckli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med. 2007;48(5):736-743.
6. Schlatter P, Beglinger C, Drewe J, Gutmann H. Glucagon-like peptide1 receptor expression in primary porcine proximal tubular cells. Regul Pept. 2007;141(1-3):120-128.
7. Park CW, Kim HW, Ko SH, et al. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol. 2007;18(4):1227-1238.
8. Kodera R, Shikata K, Kataoka H, et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia. 2011;54(4):965-978.
9. Crajoinas RO, Oricchio FT, Pessoa TD, et al. Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am J Physiol Renal Physiol. 2011;301(2): F355-F363.
10. Liu WJ, Xie SH, Liu YN, et al. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther. 2012;340(2):248-255.
11. Moreno C, Mistry M, Roman RJ. Renal effects of glucagon-like peptide in rats. Eur J Pharmacol. 2002;434(3):163-167.
12. Carraro-Lacroix LR, Malnic G, Girardi ACC. Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells. Am J Physiol Renal Physiol. 2009;297(6):F1647-F1655.
13. Gutzwiller JP, Tschopp S, Bock A, et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab. 2004;89(6):3055-3061.
14. Gutzwiller JP, Hruz P, Huber AR, et al. Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans. Digestion. 2006;73(2-3):142-150.
15. Hendarto H, Inoguchi T, Maeda Y, et al. GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases. Metabolism. 2012;61(10):1422-1434.
16. Kappelgaard AM, Nielsen MD, Giese J. Measurement of angiotensin II in human plasma: technical modifications and practical experience. Clin Chim Acta. 1976;67(3):299-306.
17. Katsurada A, Hagiwara Y, Miyashita K, et al. Novel sandwich ELISA for human angiotensinogen. Am J Physiol Renal Physiol. 2007;293(3):F956-F960.
18. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes. 1994;43(4):535-539.
19. Armitage P, Berry G. Matthews JNS. Stat Methods Med Res. 2002; 4:627-634.
20. Thomsen K. Lithium clearance: a new method for determining proximal and distal tubular reabsorption of sodium and water. Nephron. 1984;37(4):217-223.
21. Kobori H, Harrison-Bernard LM, Navar LG. Urinary excretion of angiotensinogen reflects intrarenal angiotensinogen production. Kidney Int. 2002;61(2):579-585.
22. Persson P, Hansell P, Palm F. Tubular reabsorption and diabetes-induced glomerular hyperfiltration. Acta Physiol (Oxf). 2010; 200(1):3-10.
23. Mendis B, Simpson E, Macdonald I, Mansell P. Investigation of the haemodynamic effects of exenatide in healthy male subjects. Br J Clin Pharmacol. 2012;74(3):437-444.
24. Bharucha AE, Charkoudian N, Andrews CN, et al. Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans. Am J Physiol Regul Integr Comp Physiol. 2008;295(3):R874-R880.
25. Edwards CM, Todd JF, Ghatei MA, Bloom SR. Subcutaneous glucagon-like peptide-1 (7-36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects. Clin Sci (Lond). 1998; 95(6):719-724.
26. Yu M, Moreno C, Hoagland KM, et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertension. 2003;21(6):1125-1135.
27. Okerson T, Chilton RJ. The cardiovascular effects of GLP-1 receptor agonists. Cardiovasc Ther. 2012;30(3):e146-e155.
28. Kobori H, Navar LG. Urinary angiotensinogen as a novel biomarker of intrarenal renin-angiotensin system in chronic kidney disease. Int Rev Thromb. 2011;6(2):108-116.
29. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev. 2006;86(3):747-803.
30. Ellis B, Li XC, Miguel-Qin E, Gu V, Zhuo JL. Review: evidence for a functional intracellular angiotensin system in the proximal tubule of the kidney. Am J Physiol Regul Integr Comp Physiol. 2012; 302(5):R494-R509.
31. Mima A, Hiraoka-Yamomoto J, Li Q, et al. Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCβ activation in diabetes. Diabetes. 2012;61(11):2967-2979.
32. Hirata K, Kume S, Araki SI, et al. Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model. Biochem Biophys Res Commun. 2009;380(1):44-49.
33. Ishibashi Y, Matsui T, Ojima A, et al. Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A. Microvasc Res. 2012;84(3):395-398.
34. Vejakama P, Thakkinstian A, Lertrattananon D, Ingsathit A, Ngarmukos C, Attia J. Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia. 2012;55(3):566-578.
35. Houillier P, Chambrey R, Achard JM, Froissart M, Poggioli J, Paillard M. Signaling pathwaysinthe biphasic effect of angiotensin II on apical Na/H antiport activity in proximal tubule. Kidney Int. 1996; 50(5):1496-1505.
36. Fliser D, Schaefer F, Schmid D, Veldhuis JD, Ritz E. Angiotensin II affects basal, pulsatile, and glucose-stimulated insulin secretion in humans. Hypertension. 1997;30(5):1156-1161.